

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




Fig. 1




Fig. 2

* Extraction process of opioids for anti-abuse properties is the same for figure 1 and figure 2.

** Marketed Oxycodone formulation from Purdue Pharma.

Results of Abuse Testing

Hydrocodone 5 mg Formulations




Fig. 3.

Dissolution Profiles of Various Hydrocodone Formulations

Method: USP 2 Paddles,
50 RPM, 500 mL Purified Water,
Absorbance @ 280 nm





Fig. 4


I



II



III



IV




Figure 5a




Figure 5b




Figure 5c




Figure 6: Process Flow Chart

Dissolution Profiles of HCBT Tablets




Fig 7